Annual EBITDA
-$1.83 M
-$1.80 M-5071.47%
31 December 2023
Summary:
Bellevue Life Sciences Acquisit annual earnings before interest, taxes, depreciation & amortization is currently -$1.83 million, with the most recent change of -$1.80 million (-5071.47%) on 31 December 2023. During the last 3 years, it has fallen by -$1.83 million (-55375.76%). BLACU annual EBITDA is now -133.27% below its all-time high of $5.50 million, reached on 01 December 2020.BLACU EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$454.10 K
+$21.40 K+4.50%
30 September 2024
Summary:
Bellevue Life Sciences Acquisit quarterly earnings before interest, taxes, depreciation & amortization is currently -$454.10 thousand, with the most recent change of +$21.40 thousand (+4.50%) on 30 September 2024. Over the past year, it has dropped by -$43.70 thousand (-10.65%). BLACU quarterly EBITDA is now -454000.00% below its all-time high of -$100.00, reached on 01 September 2021.BLACU Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$2.24 M
-$43.70 K-1.99%
30 September 2024
Summary:
Bellevue Life Sciences Acquisit TTM earnings before interest, taxes, depreciation & amortization is currently -$2.24 million, with the most recent change of -$43.70 thousand (-1.99%) on 30 September 2024. Over the past year, it has dropped by -$1.26 million (-128.08%). BLACU TTM EBITDA is now -149386.67% below its all-time high of -$1500.00, reached on 01 June 2022.BLACU TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BLACU EBITDA Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -5071.5% | -10.7% | -128.1% |
3 y3 years | -10000.0% | -10000.0% | -10000.0% |
5 y5 years | -268.4% | - | - |
BLACU EBITDA High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | <-9999.0% | at low | <-9999.0% | +47.3% | <-9999.0% | at low |
5 y | 5 years | -133.3% | at low | <-9999.0% | +47.3% | <-9999.0% | at low |
alltime | all time | -133.3% | +90.9% | <-9999.0% | +47.3% | <-9999.0% | at low |
Bellevue Life Sciences Acquisit EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$454.10 K(-4.5%) | -$2.24 M(+2.0%) |
June 2024 | - | -$475.50 K(+5.5%) | -$2.20 M(+9.7%) |
Mar 2024 | - | -$450.80 K(-47.7%) | -$2.00 M(+9.4%) |
Dec 2023 | -$1.83 M(+5071.5%) | -$861.90 K(+110.0%) | -$1.83 M(+86.2%) |
Sept 2023 | - | -$410.40 K(+46.4%) | -$983.10 K(+65.9%) |
June 2023 | - | -$280.30 K(+0.8%) | -$592.70 K(+89.1%) |
Mar 2023 | - | -$278.10 K(+1844.8%) | -$313.40 K(+785.3%) |
Dec 2022 | -$35.40 K | - | - |
Dec 2022 | - | -$14.30 K(-28.5%) | -$35.40 K(+65.4%) |
Sept 2022 | - | -$20.00 K(+1900.0%) | -$21.40 K(+1326.7%) |
June 2022 | - | -$1000.00(+900.0%) | -$1500.00(-53.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$100.00(-66.7%) | -$3200.00(+3.2%) |
Dec 2021 | -$3300.00(-100.1%) | -$300.00(+200.0%) | -$3100.00(+10.7%) |
Sept 2021 | - | -$100.00(-96.3%) | -$2800.00(+3.7%) |
June 2021 | - | -$2700.00 | -$2700.00 |
Dec 2020 | $5.50 M(-1207.2%) | - | - |
Dec 2019 | -$497.00 K(-90.7%) | - | - |
Dec 2018 | -$5.36 M(-69.4%) | - | - |
Dec 2017 | -$17.51 M(+6.1%) | - | - |
Dec 2016 | -$16.51 M(-17.8%) | - | - |
Dec 2015 | -$20.07 M(+324.9%) | - | - |
Dec 2014 | -$4.72 M | - | - |
FAQ
- What is Bellevue Life Sciences Acquisit annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Bellevue Life Sciences Acquisit?
- What is Bellevue Life Sciences Acquisit annual EBITDA year-on-year change?
- What is Bellevue Life Sciences Acquisit quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Bellevue Life Sciences Acquisit?
- What is Bellevue Life Sciences Acquisit quarterly EBITDA year-on-year change?
- What is Bellevue Life Sciences Acquisit TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Bellevue Life Sciences Acquisit?
- What is Bellevue Life Sciences Acquisit TTM EBITDA year-on-year change?
What is Bellevue Life Sciences Acquisit annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BLACU is -$1.83 M
What is the all time high annual EBITDA for Bellevue Life Sciences Acquisit?
Bellevue Life Sciences Acquisit all-time high annual earnings before interest, taxes, depreciation & amortization is $5.50 M
What is Bellevue Life Sciences Acquisit annual EBITDA year-on-year change?
Over the past year, BLACU annual earnings before interest, taxes, depreciation & amortization has changed by -$1.80 M (-5071.47%)
What is Bellevue Life Sciences Acquisit quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BLACU is -$454.10 K
What is the all time high quarterly EBITDA for Bellevue Life Sciences Acquisit?
Bellevue Life Sciences Acquisit all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$100.00
What is Bellevue Life Sciences Acquisit quarterly EBITDA year-on-year change?
Over the past year, BLACU quarterly earnings before interest, taxes, depreciation & amortization has changed by -$43.70 K (-10.65%)
What is Bellevue Life Sciences Acquisit TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BLACU is -$2.24 M
What is the all time high TTM EBITDA for Bellevue Life Sciences Acquisit?
Bellevue Life Sciences Acquisit all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1500.00
What is Bellevue Life Sciences Acquisit TTM EBITDA year-on-year change?
Over the past year, BLACU TTM earnings before interest, taxes, depreciation & amortization has changed by -$1.26 M (-128.08%)